Carbon Dioxide (Carbogen) for the Treatment of Febrile Seizures

• Status: Terminated
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this clinical trail is to evaluate the efficacy of a Carbogen inhalation in patients with febrile seizures compared to a placebo-inhalation.

Further aims are the evaluation of the safety of the Carbogen inhalation via a low-pressure can with a breathing mask in a home-setting, the manageability of the Carbogen inhalation via a low pressure can with a breathing mask in a home-setting or on the way (mobility), the quality of life of the parents and children using the low pressure can with a breathing mask in a home-setting or on the way (mobility) and the contentment and anxiety of the parents.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Charite University, Berlin, Germany
• Collaborator: Charité Neurocure AG Flöel

Criteria

Inclusion Criteria:

• condition after febrile seizure

• age 12 months to 5 years

• written informed consent

Exclusion Criteria:

• severe other organic disease

• meningitis as possible cause for the cerebral seizure

• neurologic disease or cerebral dysplasia

• cerebrale seizures without fever in the medical history

• hypersynchronic eeg activity

• disorder of the respiratory tract (Asthma e.g.)